Efficacy analysis of targeted P53 therapy in solid tumors
- PMID: 40694182
- DOI: 10.1007/s12032-025-02930-y
Efficacy analysis of targeted P53 therapy in solid tumors
Abstract
Mutations in the oncogene p53 are present in nearly all types of carcinomas and are commonly inactivated in certain tumor types, resulting in a poor prognosis for these patients. In contrast to the prevailing perspective that targeting p53 protein is not feasible, an increasing number of scholars have found that strategies such as directly or indirectly targeting P53 to enhance or restore the function of wild-type P53, or degrading mutant P53 so that the gain of function caused by it disappears, as well as modulating the immune response and cellular metabolism, can control the progression of tumor cells in different states of P53. This article aims to provide a comprehensive overview of the most recent targeted drugs for solid tumors with different P53 status. At the same time, it conducts a thorough analysis of the efficacy of relevant drugs in patients and puts forward possible reasons for the poor efficacy of some medicines.
Keywords: Clinical efficacy; Immunity; P53; Solid tumors.
© 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Conflict of interest statement
Declarations. Competing interests: The authors declare no competing interests. Ethics approval: Not applicable. Consent for publication: Not applicable. Consent to participate: Not applicable.
Similar articles
-
The Black Book of Psychotropic Dosing and Monitoring.Psychopharmacol Bull. 2024 Jul 8;54(3):8-59. Psychopharmacol Bull. 2024. PMID: 38993656 Free PMC article. Review.
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320. Health Technol Assess. 2001. PMID: 12065068
-
Systemic treatments for metastatic cutaneous melanoma.Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2. Cochrane Database Syst Rev. 2018. PMID: 29405038 Free PMC article.
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4. Cochrane Database Syst Rev. 2021. Update in: Cochrane Database Syst Rev. 2022 May 23;5:CD011535. doi: 10.1002/14651858.CD011535.pub5. PMID: 33871055 Free PMC article. Updated.
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2020 Jan 9;1(1):CD011535. doi: 10.1002/14651858.CD011535.pub3. Cochrane Database Syst Rev. 2020. Update in: Cochrane Database Syst Rev. 2021 Apr 19;4:CD011535. doi: 10.1002/14651858.CD011535.pub4. PMID: 31917873 Free PMC article. Updated.
References
-
- Friedman PN, Chen X, Bargonetti J, Prives C. The p53 protein is an unusually shaped tetramer that binds directly to DNA. Proc Natl Acad Sci U S A. 1993;90:3319–23.
-
- Joerger AC, Fersht AR. The tumor suppressor p53: from structures to drug discovery. Cold Spring Harb Perspect Biol. 2010;2: a000919.
-
- Kastenhuber ER, Lowe SW. Putting p53 in context. Cell. 2017;170:1062–78.
-
- Levine AJ. p53: 800 million years of evolution and 40 years of discovery. Nat Rev Cancer. 2020;20:471–80.
-
- Ding Y, Xue H, Ding X, Zhao Y, Zhao Z, Wang D, et al. On the complexity measures of mutation hotspots in human P53 protein. Chaos. 2020;30: 073118.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous